Biotechnology Business

AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results

Published in Law and Health Weekly, May 24th, 2008

AEterna Zentaris Inc. (NASDAQ: AEZS)(NASDAQ:TSX:)(NASDAQ:AEZ), a global biopharmaceutical company focused on endocrinology and oncology, reported financial and operating results for the first quarter ended March 31, 2008. First Quarter 2008 Highlights - Cetrorelix: first patients treated in second efficacy trial of the

Phase 3 program in benign prostatic hyperplasia (BPH); - AEZS-108: first patients treated in Phase 2 trial in ovarian and

endometrial cancers; - Miltefosine (Impavido(R)): rights sold to Paladin Labs Inc. (TSX:PLB)

for approximately $8.9 million. Subsequent to First Quarter End - Cetrorelix: recruitment of 600...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2008-05-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry